标题
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 16, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-09-05
DOI
10.1186/s13045-023-01499-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
- (2023) Esther Schoutrop et al. Journal for ImmunoTherapy of Cancer
- LAG-3+ tumor-infiltrating lymphocytes ameliorates overall survival in triple-negative breast cancer patients
- (2023) Guoming Hu et al. Frontiers in Oncology
- Increasing cure rates of solid tumors by immune checkpoint inhibitors
- (2023) Weijie Ma et al. Experimental Hematology & Oncology
- STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2
- (2023) Amer M Zeidan et al. Future Oncology
- Exploiting RIG-I-like receptor pathway for cancer immunotherapy
- (2023) Yangfu Jiang et al. Journal of Hematology & Oncology
- Novel strategies for cancer immunotherapy: counter-immunoediting therapy
- (2023) Shaochuan Liu et al. Journal of Hematology & Oncology
- Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors
- (2023) Fan Yang et al. Frontiers in Immunology
- T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review
- (2023) Gerardo Cazzato et al. Cancers
- Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins
- (2023) Yidan Qiao et al. Cancer Communications
- Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
- (2023) Mengke Niu et al. Journal of Hematology & Oncology
- TIGIT is a key inhibitory checkpoint receptor in lymphoma
- (2023) James Godfrey et al. Journal for ImmunoTherapy of Cancer
- Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
- (2022) Muthulekha Swamydas et al. Journal of Hematology & Oncology
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32
- (2022) Kang Wu et al. Frontiers in Pharmacology
- An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models
- (2022) Xin Chen et al. Frontiers in Immunology
- The role of phosphatidylserine on the membrane in immunity and blood coagulation
- (2022) Jiao Wang et al. Biomarker Research
- Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer
- (2022) Marion Thibaudin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sequential single cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin's lymphoma
- (2022) Zachary Jackson et al. Cancer Discovery
- Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function
- (2022) Franziska Blaeschke et al. Frontiers in Immunology
- Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR ‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial
- (2022) Cunte Chen et al. Clinical and Translational Medicine
- Heterogeneity of the tumor immune microenvironment and its clinical relevance
- (2022) Qingzhu Jia et al. Experimental Hematology & Oncology
- Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer
- (2022) Junfen Xu et al. CLINICAL CANCER RESEARCH
- Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).
- (2022) Gerald Steven Falchook et al. JOURNAL OF CLINICAL ONCOLOGY
- Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
- (2022) Liangliang Xu et al. Journal of Hematology & Oncology
- Combination of two novel blocking antibodies, anti-PD-1 antibody ezabenlimab (BI 754091) and anti-LAG-3 antibody BI 754111, leads to increased immune cell responses
- (2022) Markus Zettl et al. OncoImmunology
- 745P Clinical activity, safety, and PK/PD from the first in human study (NP41300) of RO7247669, a PD1-LAG3 bispecific antibody
- (2022) K.S. Rohrberg et al. ANNALS OF ONCOLOGY
- 486P AK130, a first-in-class Fc-mutant anti-TIGIT antibody fused with TGF-βRII protein, elicits potent anti-tumor efficacy in pre-clinical studies
- (2022) J. Min et al. ANNALS OF ONCOLOGY
- Negative Regulation of RIG-I by Tim-3 Promotes H1N1 Infection
- (2022) Qingzhu Shi et al. IMMUNOLOGICAL INVESTIGATIONS
- LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
- (2022) Natalia Sauer et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
- (2022) Yuchen Wang et al. Journal of Hematology & Oncology
- The journey of CAR-T therapy in hematological malignancies
- (2022) Junru Lu et al. Molecular Cancer
- TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
- (2022) Vivian Changying Jiang et al. Molecular Cancer
- Immunotherapeutic progress and application of bispecific antibody in cancer
- (2022) Jingyue Kang et al. Frontiers in Immunology
- Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
- (2022) Marina Natoli et al. Journal for ImmunoTherapy of Cancer
- Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
- (2022) Diana Cortes-Selva et al. BLOOD
- A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance
- (2022) Timothy A. Yap et al. CLINICAL CANCER RESEARCH
- Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
- (2021) Matthew D. Hellmann et al. CLINICAL CANCER RESEARCH
- Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
- (2021) James J. Harding et al. CLINICAL CANCER RESEARCH
- LAG-3 expression in the inflammatory microenvironment of glioma
- (2021) Maximilian J. Mair et al. JOURNAL OF NEURO-ONCOLOGY
- Implication of TIGIT+ human memory B cells in immune regulation
- (2021) Md Mahmudul Hasan et al. Nature Communications
- Phase I/Ib clinical trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination With Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
- (2021) Giuseppe Curigliano et al. CLINICAL CANCER RESEARCH
- Correction: Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
- (2021) Xiaoyuan Huang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Next generation of immune checkpoint inhibitors and beyond
- (2021) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Improving Breast Cancer Responses to Immunotherapy—a Search for the Achilles Heel of the Tumor Microenvironment
- (2021) Sarah Jenkins et al. Current Oncology Reports
- Bispecific Antibodies: From Research to Clinical Application
- (2021) Jiabing Ma et al. Frontiers in Immunology
- One Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia
- (2021) Zhiding Wang et al. Frontiers in Immunology
- LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer
- (2021) Lena Seifert et al. Cancers
- LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
- (2021) Christian Sordo-Bahamonde et al. Cancers
- LAG3 and its emerging role in cancer immunotherapy
- (2021) Miao Wang et al. Clinical and Translational Medicine
- Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors
- (2021) Antoine Hollebecque et al. CLINICAL CANCER RESEARCH
- AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
- (2021) Lingying Wu et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
- (2021) Wenjing Qian et al. Journal of Hematology & Oncology
- Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells
- (2021) Wen-Hsin Sandy Lee et al. MOLECULAR CANCER THERAPEUTICS
- Single‐Cell RNA‐Seq of T Cells in B‐ALL Patients Reveals an Exhausted Subset with Remarkable Heterogeneity
- (2021) Xiaofang Wang et al. Advanced Science
- TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
- (2021) Zhouhong Ge et al. Frontiers in Immunology
- PD-1 and TIGIT Are Highly Co-Expressed on CD8+ T Cells in AML Patient Bone Marrow
- (2021) Ling Xu et al. Frontiers in Oncology
- The landscape of bispecific T cell engager in cancer treatment
- (2021) Shujie Zhou et al. Biomarker Research
- LAG-3 Expression Predicts Outcome in Stage II Colon Cancer
- (2021) Gaëlle Rhyner Agocs et al. Journal of Personalized Medicine
- The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
- (2021) Andrea Botticelli et al. Journal of Personalized Medicine
- First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
- (2021) J. Niu et al. ANNALS OF ONCOLOGY
- Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents
- (2021) Andrew M. Brunner et al. BLOOD
- PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells
- (2021) Young-Ho Lee et al. MOLECULAR THERAPY
- The foundations of immune checkpoint blockade and the ipilimumab approval decennial
- (2021) Alan J. Korman et al. NATURE REVIEWS DRUG DISCOVERY
- Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
- (2021) Songbo Zhao et al. Journal for ImmunoTherapy of Cancer
- Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
- (2021) Peipei Wang et al. Journal for ImmunoTherapy of Cancer
- Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
- (2021) Franziska Brauneck et al. Frontiers in Medicine
- Recent advances and challenges of bispecific antibodies in solid tumors
- (2021) Yuze Wu et al. Experimental Hematology & Oncology
- Light-induced radiosynthesis of 89ZrDFO-azepin-onartuzumab for imaging the hepatocyte growth factor receptor
- (2020) Simon Klingler et al. JOURNAL OF NUCLEAR MEDICINE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
- (2020) Hirofumi Ohmura et al. BRITISH JOURNAL OF CANCER
- FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
- (2020) Matthew Kraman et al. CLINICAL CANCER RESEARCH
- A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.
- (2020) Jason J. Luke et al. JOURNAL OF CLINICAL ONCOLOGY
- TIGIT enhances CD4 + regulatory T‐cell response and mediates immune suppression in a murine ovarian cancer model
- (2020) Fengzhen Chen et al. Cancer Medicine
- The immune checkpoints Cytotoxic T lymphocyte antigen-4 and Lymphocyte activation gene-3 expression is up-regulated in acute myeloid leukemia
- (2020) Sara M. Radwan et al. HLA
- Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
- (2020) Adi Reches et al. Journal for ImmunoTherapy of Cancer
- A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects
- (2020) Fang Yang et al. JOURNAL OF IMMUNOLOGY
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- TIGIT in cancer immunotherapy
- (2020) Joe-Marc Chauvin et al. Journal for ImmunoTherapy of Cancer
- Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
- (2019) Sneha Berry et al. Journal for ImmunoTherapy of Cancer
- AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer
- (2019) Luc Dirix et al. Future Oncology
- Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
- (2019) Nataliya Volodymyrivna Uboha et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1
- (2019) Irma Herrera-Camacho et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
- (2019) Yaru Tian et al. Journal of Hematology & Oncology
- Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy
- (2019) Paola Dama et al. Journal for ImmunoTherapy of Cancer
- Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 Knock-In Mice
- (2019) Elena Burova et al. MOLECULAR CANCER THERAPEUTICS
- Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma
- (2019) Lei Wu et al. Cancer Immunology Research
- 1197PA phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
- (2019) A Spreafico et al. ANNALS OF ONCOLOGY
- Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas
- (2019) Carlos A Murga-Zamalloa et al. JOURNAL OF CLINICAL PATHOLOGY
- TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer
- (2019) Jiefei Han et al. Cancer Immunology Research
- TIGIT as an emerging immune checkpoint
- (2019) H. Harjunpää et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells
- (2018) Dongliang Zhang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT
- (2018) Long Liu et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma
- (2018) Camille Guillerey et al. BLOOD
- Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
- (2018) Marina Wierz et al. BLOOD
- Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
- (2018) Xiaolei Li et al. Cellular & Molecular Immunology
- T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
- (2018) Long Liu et al. CLINICAL IMMUNOLOGY
- Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction
- (2018) Bhagyashree Bhagwat et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract 2784: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation
- (2018) Michael Hedvat et al. CANCER RESEARCH
- Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies
- (2018) David Savitsky et al. CANCER RESEARCH
- Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
- (2018) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Induction and transcriptional regulation of the co-inhibitory gene module in T cells
- (2018) Norio Chihara et al. NATURE
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Programmed cell death protein 1 activation preferentially inhibits CD28.CAR–T cells
- (2018) Sergey N. Zolov et al. CYTOTHERAPY
- Engineering therapeutic bispecific antibodies using CrossMab technology
- (2018) Christian Klein et al. METHODS
- TSR-033, a novel therapeutic antibody targeting LAG-3 enhances T cell function and the activity of PD-1 blockade in vitro and in vivo
- (2018) Srimoyee Ghosh et al. MOLECULAR CANCER THERAPEUTICS
- Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells
- (2018) Xiu-Man Zhou et al. Frontiers in Immunology
- TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
- (2017) Wenwen Du et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
- (2017) Yayi He et al. Journal of Thoracic Oncology
- Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses
- (2017) Valerie Chew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of Tim-3 as a therapeutic target in prostate cancer
- (2017) Yongrui Piao et al. TUMOR BIOLOGY
- High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity
- (2017) Liangjing Xu et al. Oncotarget
- CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
- (2016) Xiaojuan Liu et al. CELL RESEARCH
- T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
- (2016) Y. Kong et al. CLINICAL CANCER RESEARCH
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
- (2016) Jennifer E. Kim et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Upregulation of T-cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Monocytes/Macrophages Associates with Gastric Cancer Progression
- (2016) Zhenxin Wang et al. IMMUNOLOGICAL INVESTIGATIONS
- Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma
- (2016) Zhu Li et al. MEDICINE
- LAG3 facilitates cell-to-cell spread of α-synuclein pathology
- (2016) Heather Wood Nature Reviews Neurology
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
- (2016) Wei-Wei Deng et al. OncoImmunology
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Dan R. Littman CELL
- A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression
- (2015) Yoshikane Kikushige et al. Cell Stem Cell
- FDA Approval: Blinatumomab
- (2015) D. Przepiorka et al. CLINICAL CANCER RESEARCH
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
- (2015) Wenjiang Yan et al. GUT
- Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
- (2015) Chamutal Gur et al. IMMUNITY
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226
- (2015) Christopher A. Fuhrman et al. JOURNAL OF IMMUNOLOGY
- Effect of DR4 promoter methylation on the TRAIL-induced apoptosis in lung squamous carcinoma cell
- (2015) WENWU WANG et al. ONCOLOGY REPORTS
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
- (2015) Chiao-Wen Kang et al. Scientific Reports
- Tim-3 and Tim-4 as the potential targets for antitumor therapy
- (2015) Lin Cheng et al. Human Vaccines & Immunotherapeutics
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
- (2015) T. Kouo et al. Cancer Immunology Research
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- Treg Cells Expressing the Coinhibitory Molecule TIGIT Selectively Inhibit Proinflammatory Th1 and Th17 Cell Responses
- (2014) Nicole Joller et al. IMMUNITY
- Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II
- (2014) Bitao Liang et al. JOURNAL OF IMMUNOLOGY
- Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion
- (2014) Robert L. Ferris et al. JOURNAL OF IMMUNOLOGY
- Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3
- (2014) Chiara Camisaschi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes
- (2014) L. E. Macdonald et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
- (2014) A. J. Murphy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Prognostic Value of T Cell Immunoglobulin Mucin-3 in Prostate Cancer
- (2013) Yong-Rui Piao et al. Asian Pacific Journal of Cancer Prevention
- Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR
- (2013) Noa Stanietsky et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma
- (2013) S. R. Goding et al. JOURNAL OF IMMUNOLOGY
- TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial-mesenchymal transition-specific biomarkers
- (2013) YONGJUN SHANG et al. Oncology Letters
- Ectopic Expression of TIM-3 in Lung Cancers
- (2012) Xuewei Zhuang et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma
- (2012) Zhi-Zhang Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion
- (2012) Manu Rangachari et al. NATURE MEDICINE
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
- (2011) N. Joller et al. JOURNAL OF IMMUNOLOGY
- TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
- (2010) Yoshikane Kikushige et al. Cell Stem Cell
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells
- (2010) V. Dardalhon et al. JOURNAL OF IMMUNOLOGY
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started